Analysts Offer Insights on Healthcare Companies: Corvus Pharmaceuticals (CRVS) and Legend Biotech (LEGN)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Corvus Pharmaceuticals (CRVS – Research Report) and Legend Biotech (LEGN – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Corvus Pharmaceuticals (CRVS)
In a report released today, Jeff Jones from Oppenheimer reiterated a Buy rating on Corvus Pharmaceuticals, with a price target of $32.00. The company’s shares closed last Tuesday at $21.41.
According to TipRanks.com, Jones is a 4-star analyst with an average return of
Currently, the analyst consensus on Corvus Pharmaceuticals is a Strong Buy with an average price target of $25.00, implying an 85.0% upside from current levels. In a report released yesterday, TipRanks – Google also upgraded the stock to Buy with a $9.00 price target.
See the top stocks recommended by analysts >>
Legend Biotech (LEGN)
Oppenheimer analyst Kostas Biliouris reiterated a Buy rating on Legend Biotech today and set a price target of $75.00. The company’s shares closed last Tuesday at $23.42.
According to TipRanks.com, Biliouris is a 1-star analyst with an average return of
Legend Biotech has an analyst consensus of Strong Buy, with a price target consensus of $67.30, which is a 210.1% upside from current levels. In a report issued on January 8, RBC Capital also maintained a Buy rating on the stock with a $66.00 price target.
